BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00097357
First received: November 22, 2004
Last updated: February 27, 2010
Last verified: November 2008
  Purpose

The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.


Condition Intervention Phase
Venous Thrombosis
Pulmonary Embolism
Drug: Apixaban
Drug: Enoxaparin
Drug: Warfarin
Drug: Enoxaparin Placebo
Drug: Apixaban Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 2 Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Determine the dose-response relationship among the 3 QD and 3 BID doses of BMS-562247 on the composite endpoint of adjudicated VTE events and all-cause death in subjects treated with study medication for 12 +/-2 days following surgery [ Time Frame: throughout the study ]

Secondary Outcome Measures:
  • Assess the effect of QD and BID dose of BMS-562247 vs subcutaneous 30 mg q12h enoxaparin and warfarin on the composite endpoint of adjudication VTE events and all-cause death in subjects treated for 12 +/-2 days following surgery [ Time Frame: throughout the study ]
  • Assess the effect of each QD and BID dose of BMS-562247 versus subcutaneous 30 mg q12h enoxaparin and oral warfarin on the incidence of adjudicated major bleeding events in subjects treated with study medication for 12 +/-2 days following surgery [ Time Frame: throughout the study ]
  • Assess the effect of each QD and BID dose of BMS-562247 versus subcutaneous 30 mg q12h enoxaparin and oral warfarin on the incidence of adjudicated minor bleeding events in subjects treated with study medication for 12 +/-2 days following surgery [ Time Frame: throughout the study ]
  • To determine the pharmacokinetic (PK) profile of BMS-562247 and the relationship to dose and dose schedule [ Time Frame: throughout the study ]

Enrollment: 1238
Study Start Date: October 2004
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A1

Apixaban: 2.5 mg, BID

PLUS

Enoxaparin Placebo

Drug: Apixaban
Tablets, Oral, 12 +/- 2 days
Other Name: BMS-562247
Drug: Enoxaparin Placebo
Injection, SQ, BID, 12 +/- 2 days
Experimental: A2

Apixaban: 5 mg, BID

PLUS

Enoxaparin Placebo

Drug: Apixaban
Tablets, Oral, 12 +/- 2 days
Other Name: BMS-562247
Drug: Enoxaparin Placebo
Injection, SQ, BID, 12 +/- 2 days
Experimental: A3

Apixaban: 10 mg, BID

PLUS

Enoxaparin Placebo

Drug: Apixaban
Tablets, Oral, 12 +/- 2 days
Other Name: BMS-562247
Drug: Enoxaparin Placebo
Injection, SQ, BID, 12 +/- 2 days
Experimental: A4

Apixaban: 5 mg, QD

PLUS

Enoxaparin Placebo

Drug: Apixaban
Tablets, Oral, 12 +/- 2 days
Other Name: BMS-562247
Drug: Enoxaparin Placebo
Injection, SQ, BID, 12 +/- 2 days
Experimental: A5

Apixaban: 10 mg, QD

PLUS

Enoxaparin Placebo

Drug: Apixaban
Tablets, Oral, 12 +/- 2 days
Other Name: BMS-562247
Drug: Enoxaparin Placebo
Injection, SQ, BID, 12 +/- 2 days
Experimental: A6

Apixaban: 20 mg, QD

PLUS

Enoxaparin Placebo

Drug: Apixaban
Tablets, Oral, 12 +/- 2 days
Other Name: BMS-562247
Drug: Enoxaparin Placebo
Injection, SQ, BID, 12 +/- 2 days
Active Comparator: E1

Enoxaparin: 30 mg

PLUS

Apixaban Placebo

Drug: Enoxaparin
Injection, SQ, Q12H, 12 +/- 2 days
Drug: Apixaban Placebo
Tablets, Oral, BID, 12 +/- 2 days
Active Comparator: W1
Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0
Drug: Warfarin
Tablets, Oral, QD, 12 +/- 2 days

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Undergoing elective unilateral total knee replacement surgery.
  • Willing and able to undergo bilateral ascending contrast venography.
  • Able to inject (by self or caregiver) study medication subcutaneously.

Exclusion Criteria:

  • Women of childbearing potential.
  • Women who are pregnant or breastfeeding.
  • Under some conditions, subjects weighing more than 300 lbs. (136kg) and/or Body Mass Index (BMI) >=35 kg/m2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00097357

  Hide Study Locations
Locations
United States, Alabama
Local Institution
Birmingham, Alabama, United States
Local Institution
Mobile, Alabama, United States
Local Institution
Northport, Alabama, United States
United States, Arizona
Local Institution
Phoenix, Arizona, United States
Local Institution
Scottsdale, Arizona, United States
Local Institution
Tucson, Arizona, United States
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
Beverly Hills, California, United States
Local Institution
Encinitas, California, United States
Local Institution
Fountain Valley, California, United States
Local Institution
La Jolla, California, United States
Local Institution
La Mesa, California, United States
Local Institution
Long beach, California, United States
Local Institution
Montclair, California, United States
Local Institution
Oakland, California, United States
Local Institution
Pasadena, California, United States
Local Institution
Sacramento, California, United States
Local Institution
San Bernardino, California, United States
Local Institution
San Diego, California, United States
Local Institution
Santa Monica, California, United States
Local Institution
Torrance, California, United States
Local Institution
Wildomar, California, United States
Local Institution
Yuba City, California, United States
United States, Colorado
Local Institution
Aurora, Colorado, United States
Local Institution
Denver, Colorado, United States
United States, Connecticut
Local Institution
Hartford, Connecticut, United States
United States, Florida
Local Institution
Bay Pines, Florida, United States
Local Institution
Brandon, Florida, United States
Local Institution
Clearwater, Florida, United States
Local Institution
Deland, Florida, United States
Local Institution
Ft. Myers, Florida, United States
Local Institution
Hollywood, Florida, United States
Local Institution
Melbourne, Florida, United States
Local Institution
Pensacola, Florida, United States
Local Institution
Sarasota, Florida, United States
Local Institution
St. Petersburg, Florida, United States
Local Institution
Tallahassee, Florida, United States
Local Institution
Winter Park, Florida, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
Local Institution
Cumming, Georgia, United States
Local Institution
Decatur, Georgia, United States
Local Institution
Suwanee, Georgia, United States
United States, Idaho
Local Institution
Boise, Idaho, United States
Local Institution
Meridian, Idaho, United States
United States, Illinois
Local Institution
Galesburg, Illinois, United States
Local Institution
Springfield, Illinois, United States
United States, Kansas
Local Institution
Wichita, Kansas, United States
United States, Kentucky
Local Institution
Lexington, Kentucky, United States
Local Institution
Madisonville, Kentucky, United States
United States, Louisiana
Local Institution
Covington, Louisiana, United States
United States, Maryland
Local Institution
Baltimore, Maryland, United States
United States, Massachusetts
Local Institution
Newton, Massachusetts, United States
United States, Michigan
Local Institution
Port Huron, Michigan, United States
United States, Mississippi
Local Institution
Jackson, Mississippi, United States
United States, New York
Local Institution
Buffalo, New York, United States
United States, North Carolina
Local Institution
Charlotte, North Carolina, United States
Local Institution
Monroe, North Carolina, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
Local Institution
Youngstown, Ohio, United States
United States, Oklahoma
Local Institution
Tulsa, Oklahoma, United States
United States, Pennsylvania
Local Institution
Havertown, Pennsylvania, United States
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Local Institution
Charleston, South Carolina, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
Houston, Texas, United States
Local Institution
Lubbock, Texas, United States
Local Institution
San Antonio, Texas, United States
United States, Virginia
Local Institution
Newport News, Virginia, United States
United States, Washington
Local Institution
Seattle, Washington, United States
United States, Wisconsin
Local Institution
Marshfield, Wisconsin, United States
Argentina
Local Institution
CAPITAL fEDERAL, Buenos Aires, Argentina
Local Institution
Prov. Buenos Aires, Buenos Aires, Argentina
Local Institution
Ciudad De Mendoza, Mendoza, Argentina
Local Institution
Godoy Cruz, Mendoza, Argentina
Local Institution
Buenos Aires, Argentina
Australia, New South Wales
Local Institution
Camperdown, New South Wales, Australia
Australia, Queensland
Local Institution
Chermside, Queensland, Australia
Local Institution
Gold Coast, Queensland, Australia
Local Institution
Herston, Queensland, Australia
Australia, South Australia
Local Institution
Bedford Park, South Australia, Australia
Australia, Victoria
Local Institution
Box Hill, Victoria, Australia
Local Institution
Clayton, Victoria, Australia
Local Institution
East Ringwood, Victoria, Australia
Local Institution
Geelong, Victoria, Australia
Local Institution
Windsor, Victoria, Australia
Canada, Alberta
Local Institution
Calgary, Alberta, Canada
Local Institution
Edmonton, Alberta, Canada
Local Institution
Red Deer, Alberta, Canada
Canada, British Columbia
Local Institution
Kelowna, British Columbia, Canada
Local Institution
Vancouver, British Columbia, Canada
Canada, Nova Scotia
Local Institution
Dartmouth, Nova Scotia, Canada
Canada, Ontario
Local Institution
Ajax, Ontario, Canada
Local Institution
Burlington, Ontario, Canada
Local Institution
Newmarket, Ontario, Canada
Local Institution
Niagara Falls, Ontario, Canada
Local Institution
Oakville, Ontario, Canada
Local Institution
Richmond Hill, Ontario, Canada
Local Institution
St. Catharines, Ontario, Canada
Local Institution
Sudbury, Ontario, Canada
Local Institution
Thunder Bay, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Waterloo, Ontario, Canada
Local Institution
Welland, Ontario, Canada
Local Institution
Weston, Ontario, Canada
Local Institution
Windsor, Ontario, Canada
Canada, Quebec
Local Institution
Montreal, Quebec, Canada
Local Institution
Ste-foy, Quebec, Canada
Local Institution
Victoriaville, Quebec, Canada
Denmark
Local Institution
Frederiksberg, Denmark
Local Institution
Herlev, Denmark
Local Institution
Horsholm, Denmark
Local Institution
Silkeborg, Denmark
Local Institution
Slagelse, Denmark
Israel
Local Institution
Haifa, Israel
Local Institution
Holon, Israel
Local Institution
Kfar Saba, Israel
Local Institution
Petach-tikva, Israel
Local Institution
Ramat Gan, Israel
Local Institution
Rehovot, Israel
Local Institution
Tel Aviv, Israel
Local Institution
Zerifin, Israel
Mexico
Local Institution
Tijuana, Baja California Sur, Mexico
Local Institution
Mexico, Distrito Federal, Mexico
Local Institution
Mexico City, Distrito Federal, Mexico
Local Institution
Mexico, Estado De Mexico, Mexico
Local Institution
Guadalajara, Jalisco, Mexico
Local Institution
Monterrey, Nuevo Leon, Mexico
Local Institution
Culiacan, Sinaloa, Mexico
Local Institution
Hermosillo, Sonora, Mexico
Local Institution
Tampico, Tamps, Tamaulipas, Mexico
Local Institution
Jalapa, Veracruz, Mexico
Local Institution
Merida, Yucatan, Mexico
Local Institution
Aguascalientes, Mexico
Local Institution
Chihuahua, Mexico
Local Institution
Veracruz, Mexico
Poland
Local Institution
Bialystock, Poland
Local Institution
Gdansk, Poland
Local Institution
Lodz, Poland
Local Institution
Lublin, Poland
Local Institution
Piekary Slaskie, Poland
Local Institution
Radom, Poland
Local Institution
Sosnowiec, Poland
Local Institution
Szczecin, Poland
Local Institution
Szczecin Zdunowo, Poland
Local Institution
Warszawa, Poland
Puerto Rico
Local Institution
Ponce, Puerto Rico
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00097357     History of Changes
Other Study ID Numbers: CV185-010
Study First Received: November 22, 2004
Last Updated: February 27, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
Prevention of deep vein thrombosis and pulmonary embolism
Preventive therapy

Additional relevant MeSH terms:
Thrombosis
Embolism
Pulmonary Embolism
Venous Thrombosis
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Thromboembolism
Warfarin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014